At the 17th Asian Societies of Cosmetic Scientists (ASCS*) Conference 2025 in Manila, Philippines, in June 2025, Ryozo Tobita, Researcher at Shiseido MIRAI Technology Institute, delivered a presentation titled "Novel approach to maintain collagen homeostasis and healthy skin via regulating the M1/M2 macrophage balance" and received the 1st Best Podium Presentation. This award, given to the best podium presentation at the conference, aims to promote the advancement and revitalization of research in cosmetics-related fields.
At this conference, Dr. Tomonobu Ezure, Fellow at Shiseido MIRAI Technology Institute, took the stage as a Keynote Speaker for the second consecutive time and delivered a lecture on "New horizon in anti-aging skin care."
*ASCS: Asian Societies of Cosmetic Scientists:
The ASCS was established for the improvement of cosmetic technologies and further development of the cosmetic industry in the Asian region with the aim of deepening mutual collaboration through active technological and cultural exchanges. The international academic conference held biennially has been a place where a multitude of latest research achievements from various Asian countries are presented, with participants engaging in lively discussions. https://www.sccj-ifscc.com/about/ascs
Collagen plays a crucial role in maintaining skin elasticity and firmness. However, the quantity and quality of collagen decrease each year due to aging and photoaging caused by ultraviolet rays. Many studies on collagen have focused on fibroblasts, the main producers of collagen. However, the roles of other cells in the dermis and their interactions with fibroblasts remain poorly understood. Shiseido has been conducting research focused on immune cells, specifically macrophages. The present study revealed that M1/M2 macrophages influence collagen homeostasis-a series of processes including "production," "maturation," "degradation," and "digestion"-and contribute to the regulation of collagen quantity and quality. Moreover, based on these findings, Shiseido has discovered a novel approach to maintain collagen homeostasis and healthy skin via agents that regulate the M1/M2 macrophage balance.
Attachments
Original document
Permalink
Disclaimer
Shiseido Co. Ltd. published this content on July 07, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 07, 2025 at 06:43 UTC.
Shiseido Co Ltd is a Japan-based company engaged in the manufacture and sale of cosmetics, toiletries, personal care products, barber and beauty products. The Company operates in seven business segments. Japan segment sells of cosmetics, toiletries, personal care products, beauty food and over-the-counter drugs in Japan. China segment and Asia Pacific segment manufacture and sell cosmetics, toiletries and personal care products respectively in China and Asia-Oceania region excluding Japan and China. Americas and Europe segment manufacture and sell cosmetics and toiletries respectively in the Americas, as well as Europe & the Middle East & Africa. Travel Retail segment sells cosmetics and toiletries in duty free shops around the world except Japan. Professional segment sells barber and beauty products. The Company also conducts the frontier science business of cosmetic raw materials and medical drugs, as well as the food and beverage business and personal care product sales business.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.